Amalgamated Bank Sells 5,554 Shares of Hologic, Inc. (NASDAQ:HOLX)

Amalgamated Bank trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 8.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 60,169 shares of the medical equipment provider’s stock after selling 5,554 shares during the quarter. Amalgamated Bank’s holdings in Hologic were worth $4,299,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Nordea Investment Management AB increased its holdings in Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after buying an additional 69,494 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in Hologic in the fourth quarter worth about $1,057,000. Pathstone Family Office LLC boosted its position in Hologic by 96.0% in the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after purchasing an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board boosted its position in Hologic by 186.7% in the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its position in Hologic by 33.5% in the fourth quarter. Natixis Advisors L.P. now owns 258,736 shares of the medical equipment provider’s stock worth $18,486,000 after purchasing an additional 64,968 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Down 0.3 %

Shares of HOLX stock opened at $75.86 on Thursday. The stock has a 50 day moving average of $76.20 and a 200 day moving average of $73.22. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The stock has a market cap of $17.70 billion, a P/E ratio of 38.70, a P/E/G ratio of 2.55 and a beta of 1.01. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $86.74.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 earnings per share. As a group, sell-side analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

Insider Transactions at Hologic

In related news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Evercore ISI boosted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Friday, May 3rd. Raymond James upped their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. UBS Group upped their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. Finally, JPMorgan Chase & Co. upped their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.56.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.